Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
Clinical trial NCT00833053 · TERMINATED
Trial details
- NCT number
- NCT00833053
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2009-10-01
- Primary completion
- 2011-04-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.